Aim to identify drug targets and drug discovery for the treatment and management of Cancer, Liver diseases and Inflammation.

_{Research Projects}

(1) National Natural Science Foundation of China (No. 82273968), Mechanism of hepatic IRF8-mediated tumor associated macrophages polarization by suppressing tumor methionine metabolism, 2023/01-2026/12, RMB560,000, in progress.

(2) Fundamental Research Funds for the Central Universities (NO.2632022ZD13), Hepatic IRF8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-PD1 therapy, 2022/01-2023/12, RMB200,000, in progress.

(3) National Natural Science Foundation of China (No. 81903656), Effect and mechanism of a novel AR antagonist candidate compound LLU-206 in PCa by interrupting in the formation of AR/ARv7 complex, 2020/01-2022/12, RMB210,000, Completed.

(4) Natural Science Foundation of Jiangsu Province (No. BK20180560), The mechanism for IRF8-AR axis in the development and Enzalutamide sensitivity of hepatocellular carcinoma, 2018/07-2021/06, RMB200,000, Completed.(5) China Postdoctoral Science Foundation (No. 2018M632430), The mechanism for IRF8-AR axis in the development and Enzalutamide sensitivity of hepatocellular carcinoma, 2019/01-2020/12, RMB50,000, Completed.

1.Wu, H.;  Li, Y.;  Shi, G.;  Du, S.;  Wang, X.;  Ye, W.;  Zhang, Z.;  Chu, Y.;  Ma, S.;  Wang, D.;  Li, Y.;  Chen, Z.;  Birnbaumer, L.;  Wang, Z.^*; Yang, Y.^*, Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy. Hepatology 2022. doi.org/10.1002/hep.32316. Online ahead of print.  (IF:17.292)

2.Li, Y.;  Chu, Y.;  Shi, G.;  Wang, X.;  Ye, W.;  Shan, C.;  Wang, D.;  Zhang, D.;  He, W.;  Jiang, J.;  Ma, S.;  Han, Y.;  Zhao, Z.;  Du, S.;  Chen, Z.;  Li, Z.;  Yang, Y.;  Wang, C.^*;  Xu, X.^*; Wu, H.^*, A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer. Acta Pharmaceutica Sinica B 2022. Online ahead of print.  (IF:14.903)

3.Shi, G.;  Zhang, Z.;  Ma, S.;  Li, Y.;  Du, S.;  Chu, Y.;  Li, Y.;  Tang, X.;  Yang, Y.;  Chen, Z.^*;  Wang, Z.^*; Wu, H.^*, Hepatic interferon regulatory factor 8 expression mediates liver ischemia/reperfusion injury in mice. Biochem Pharmacol 2021, 192, 114728. (IF: 5.858)

4.Wang, X.;  Mao, J.;  Zhou, T.;  Chen, X.;  Tu, H.;  Ma, J.;  Li, Y.;  Ding, Y.;  Yang, Y.*;  Wu, H.^*; Tang, X.^*, Hypoxia-induced myeloid derived growth factor promotes hepatocellular carcinoma progression through remodeling tumor microenvironment. Theranostics 2021, 11 (1), 209-221. (IF: 11.556)

5.Zheng, S.;  Ni, J.;  Li, Y.;  Lu, M.;  Yao, Y.;  Guo, H.;  Jiao, M.;  Jin, T.;  Zhang, H.;  Yuan, A.;  Wang, Z.;  Yang, Y.;  Chen, Z.^*;  Wu, H.^*; Hu, W.^*, 2-Methoxyestradiol synergizes with Erlotinib to suppress hepatocellular carcinoma by disrupting the PLAGL2-EGFR-HIF-1/2α signaling loop. Pharmacol Res 2021, 169, 105685. (IF: 7.658)

6.Wu, H.;  Ren, J.;  Zhao, L.;  Li, Z.;  Ye, W.;  Yang, Y.;  Wang, J.^*; Bian, J.^*, Identification of novel androgen receptor degrading agents to treat advanced prostate cancer. Eur J Med Chem 2021, 217, 113376. (IF: 6.514)

7.Wu, H.;  You, L.;  Li, Y.;  Zhao, Z.;  Shi, G.;  Chen, Z.;  Wang, Z.;  Li, X.;  Du, S.;  Ye, W.;  Gao, X.;  Duan, J.;  Cheng, Y.;  Tao, W.;  Bian, J.;  Zhou, J. R.;  Zhu, Q.; Yang, Y., Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance. Cancer Res 2020, 80 (13), 2927-2939. (IF: 12.701)

8.Wu, H.;  Zhang, L.;  Gao, X.;  Zhang, X.;  Duan, J.;  You, L.;  Cheng, Y.;  Bian, J.;  Zhu, Q.; Yang, Y.^*, Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer. Cancer Lett 2017, 385, 108-116. (IF: 6.491)